Amir Hefni is currently the Worldwide Commercial and Region Europe Head for Cell & Gene at Novartis and is based in London, UK. In his current role, he is responsible for the commercialisation of Novartis CAR-T therapy across geographies and disease areas. Prior to Novartis, Amir was the Global Asset Head for a novel oncology drug at Ipsen in partnership with Exelixis Biotech , where he was instrumental in launching multiple indications, driving significant global brand growth and developing a rich Life Cycle.
Previously, he was with Bristol-Myers Squibb (BMS) for 11 years, his last role was Executive Director, US Oncology Thoracic Lead, where he led the Lung and Head & Neck Cancer US commercial teams. Furthermore, Amir has a breadth of experience working across different markets including US, UK/Ireland and Sweden. He held various positions of increasing responsibility in the BMS commercial organization: from Business Unit Director in the UK/Ireland, Commercialization in the US to roles within the Worldwide Commercial group, General Management in Sweden and International Markets Strategy & Operations.
Amir holds a BSc and PhD in Immuno-Pharmacology from King’s College London, University of London (UK) and an MBA from Warwick Business School, University of Warwick (UK). He also completed the General Management Program (GMP) at INSEAD (FR) in 2017.